DOCSLIB.ORG

Lithium-Induced Diabetes Insipidus: Prevention and Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lithium-Induced Diabetes Insipidus: Prevention and Management Savvy Psychopharmacology Lithium-induced diabetes insipidus: Prevention and management Arnold Andreasen, PharmD Candidate, and Vicki L. Ellingrod, PharmD, FCCP r. H, age 33, was diagnosed with bipo- symptoms, such as polydipsia and polyuria, lar I disorder 9 years ago. For the past and is estimated to occur in approximately year, his mood symptoms have been 40% of patients receiving long-term lithium M 4,5 well controlled with lithium 300 mg, 3 times therapy. a day, and olanzapine, 20 mg/d. He presents to the outpatient clinic for a routine visit com- Diagnosis plaining of insomnia, daytime sleepiness, and Diagnosing lithium-induced nephrogenic Vicki L. Ellingrod, increased thirst. He also notes that his tremor diabetes insipidus (NDI) begins with a his- PharmD, FCCP has become more prominent over the last few tory of the patient’s symptoms and order- Series Editor weeks. Concerned about his symptoms, Mr. ing lab tests.5 The next step involves a wa- H’s clinician orders a comprehensive labora- ter restriction test, also known as a thirst tory panel (Table). test, to measure the patient’s ability to con- Upon further questioning, Mr. H’s physi- centrate his or her urine. Baseline serum cian determines that his insomnia is caused osmolality and electrolytes are compared by nocturnal urination, which is consistent with new values obtained after completing with fluid and electrolyte imbalances seen in the water restriction test. Healthy people Mr. H’s laboratory panel. Mr. H is diagnosed will have a 2-to-4-fold increase in urine os- with lithium-induced diabetes insipidus. molality compared with patients who have Although lithium’s exact mechanism of ac- tion is unknown, it is known that lithium Practice Points can negatively affect the kidneys.1,2 Typically, • Lithium-induced diabetes insipidus is caused by ADH resistance in the kidneys. antidiuretic hormone (ADH) regulates wa- ter permeability in the collecting duct of the • Educate patients about signs and nephron, allowing water to be reabsorbed symptoms of nephrogenic diabetes through simple diffusion in the kidney’s insipidus (NDI), such as polyuria and polydipsia. collecting duct (Figure, page 44).3 Chronic lithium use reduces or desensitizes the kid- • For all patients taking lithium, provide ney’s ability to respond to ADH. Resistance comprehensive lab monitoring at baseline and at least every 6 to 12 months. to ADH occurs when lithium accumulates in the cells of the collecting duct and inhibits • When a patient experiences NDI, consider ADH’s ability to increase water permeabil- discontinuing lithium, reducing the daily ity. This inhibition can cause some of Mr. H’s dosage, or reducing the dosing schedule. • Diuretics are a viable treatment option Mr. Andreasen is a PharmD Candidate, University of Michigan for NDI in patient’s receiving lithium. Close College of Pharmacy, and Dr. Ellingrod is the John Gideon monitoring of lithium and potassium Searle Professor of Clinical and Translational Pharmacy, and patient education about lithium are Current Psychiatry University of Michigan College of Pharmacy and School of essential. 42 July 2013 Medicine, Department of Psychiatry, Ann Arbor, MI. Savvy Psychopharmacology Table Mr. H’s lab panel with reference ranges Test Value Sodium 157 mEq/L (136 to 146 mEq/L) Potassium 4.5 mEq/L (3.5 to 5 mEq/L) Chloride 104 mEq/L (98 to 108 mEq/L) Bicarbonate 25 mEq/L (22 to 34 mEq/L) Creatinine 1.8 mg/dL (baseline 0.8 mg/dL) (0.7 to 1.3 mg/dL) Calcium 8.35 mg/dL (8.6 to 10.3 mg/dL) Blood glucose 135 mg/dL (<100 mg/dL) Urine osmolality 175 mOsm/kg (300 to 1300 mOsm/kg) Serum osmolality 365 mOsm/kg (269 to 298 mOsm/kg) Clinical Point Thyroid-stimulating hormone 0.86 mIU/L (0.4 to 4.0 mIU/L) Lithium-induced Serum lithium 1.7 mEq/L (0.6 to 1.2 mEq/L) NDI is thought to be dose-dependent and NDI. The last step includes administering quire monitoring every 3 months. Also, in- may be prevented desmopressin and differentiates between struct patients to monitor their urine out- by using the lowest central diabetes insipidus and NDI.6 put and educate them about the dangers effective lithium After desmopressin use, patients who of fluid and electrolyte imbalances and the have central diabetes insipidus will have a signs and symptoms of NDI, such as exces- dose >50% increase in urine osmolality, whereas sive thirst and urination.1,2 patients who have NDI will have <10% in- When a patient experiences lithium- crease in urine osmolality. This distinction is induced NDI, re-evaluate treatment and important because patients with central dia- dosage, including simplifying the dosing betes insipidus might have more severe dis- regimen or switching to once-daily dos- ease and might not benefit from measures ing, usually at bedtime. Once-daily dosing commonly used for lithium-induced NDI.7 results in a lower overall lithium trough, which might allow the kidneys more “drug- Prevention and management free” time.4,5 Additionally, 12-hour lithium Lithium-induced NDI is thought to be dose- levels are approximately 20% higher with dependent and may be prevented by using once-daily monitoring; continued monitor- the lowest effective dose of lithium for an in- ing is needed during this switch. Patients dividual patient. It is important that patients who have a moderate or severe form of lith- taking lithium receive basic electrolyte, he- ium-induced NDI may need to discontinue matologic, liver function, renal function, and lithium altogether. There are several options thyroid function tests at baseline and every for treating lithium-induced NDI in patients 6 to 12 months after the lithium regimen is who need to take lithium. Closely monitor stable. Additionally, lithium levels should be kidney function and lithium routinely with monitored frequently. The frequency of these these strategies. tests may range from twice weekly to every Discuss this article at 3 to 4 months or longer, depending on the Amiloride. This potassium-sparing diuretic www.facebook.com/ CurrentPsychiatry patient’s condition. This monitoring allows minimizes accumulation of lithium by in- the prescriber to quickly identify emerging hibiting collecting duct sodium channels. adverse effects. Studies have shown that amiloride can de- Patients with impaired renal function crease mean urine volume, increase urine os- and those with a urine output >3 liters a molality, and improve the kidneys’ ability to Current Psychiatry day are more susceptible to NDI and re- respond to exogenous arginine vasopressin.8 Vol. 12, No. 7 43 continued Savvy Psychopharmacology Figure Sites of action of medications on nephron Distal convoluted tubule: Site of action for hydrochlorothiazide Clinical Point Use of a thiazide Collecting duct: Site of action diuretic might for antidiuretic warrant decreasing hormone the lithium dose by Collecting duct: Site of action for as much as 50% to amiloride prevent toxicity © CREATIONS Thiazide diuretics produce mild sodium consume. Potassium and lithium levels depletion, which decreases the distal tu- must be monitored closely.9 bule delivery of sodium, therefore in- creasing water reabsorption in the collect- Nonsteroidal anti-inflammatory drugs ing duct. Hydrochlorothiazide has been (NSAIDs). These drugs’ ability to inhibit shown to reduce urine output by >50% in prostaglandin synthesis prevents pros- patients with NDI on a sodium-restricted taglandins from antagonizing actions of diet. Hydrochlorothiazide use requires ADH in the kidney. The result is increased careful monitoring of potassium and lith- urine concentration via the actions of ADH. ium levels. Use of a thiazide diuretic also Indomethacin has a greater effect than ibu- might warrant decreasing the lithium dose profen in increasing ADH’s actions on the by as much as 50% to prevent toxicity.9,10 kidney. Use of concomitant NSAIDs with lithium requires close monitoring of renal Low-sodium diet plus hydrochlorothia- function tests.11 zide. This route provides another option to decrease urine output during lithium- References 1. Ecelbarger CA. Lithium treatment and remodeling of the induced NDI. A reduction in urine output collecting duct. Am J Physiol Renal Physiol. 2006;291(1): has been shown to be directly proportional F37-38. 2. Christensen BM, Kim YH, Kwon TH, et al. Lithium treatment to a decrease in salt intake and excretion. induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Restricting sodium to <2.3 g/d is an ap- Physiol. 2006;291(1):F39-48. propriate goal for many patients to prevent 3. Francis SG, Gardner DG. Basic and clinical endocrinology. reoccurring symptoms, which is more than 7th ed. New York, NY: McGraw Hill; 2003:154-158. Current Psychiatry 4. Stone KA. Lithium-induced nephrogenic diabetes insipidus. 44 July 2013 the 3 g/d average that most Americans J Am Board Fam Pract. 1999;12(1):43-47. Savvy Psychopharmacology 5. Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009;5(5):270-276. Related Resources 6. Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol. • Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced neph- 2012;27(12):2183-2204. rogenic diabetes insipidus: renal effects of amiloride. Clin J 7. Rose BD, Post TW. Clinical physiology of acid-base and Am Soc Nephrol. 2008;3(5):1324-1331. electrolyte disorders. 5th ed. New York, NY: McGraw-Hill; • Lederer E. Lithium nephropathy. http://emedicine. 2001:754-759,782-783. medscape.com/article/242772-overview. 8. Batlle DC, von Riotte AB, Gaviria M, et al. Amelioration of polyuria by amiloride in patients receiving long-term lithium Drug Brand Names therapy. N Engl J Med. 1985;312(7):408-414.
Load more

Recommended publications
  • DDAVP Nasal Spray Is Provided As an Aqueous Solution for Intranasal Use
    DDAVP® Nasal Spray (desmopressin acetate) Rx only DESCRIPTION DDAVP® Nasal Spray (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows: Mol. wt. 1183.34 Empirical formula: C46H64N14O12S2•C2H4O2•3H2O 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate. DDAVP Nasal Spray is provided as an aqueous solution for intranasal use. Each mL contains: Desmopressin acetate 0.1 mg Sodium Chloride 7.5 mg Citric acid monohydrate 1.7 mg Disodium phosphate dihydrate 3.0 mg Benzalkonium chloride solution (50%) 0.2 mg The DDAVP Nasal Spray compression pump delivers 0.1 mL (10 mcg) of DDAVP (desmopressin acetate) per spray. CLINICAL PHARMACOLOGY DDAVP contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU. 1. The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration. 1 2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.
    [Show full text]
  • Spray Desmopressin Acetate Nasal Spray 10 Μg/Spray
    PRODUCT MONOGRAPH Pr DDAVP® Spray Desmopressin Acetate Nasal Spray 10 µg/spray Pr DDAVP® Rhinyle Desmopressin Acetate Nasal Solution 0.1 mg/mL Antidiuretic Ferring Inc. Date of Revision: 200 Yorkland Blvd, Suite 800 June 19, 2008 North York, Ontario M2J 5C1 Submission Control No: 119073 DDAVP® Spray and Rhinyle Page 1 of 23 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION................................................................................7 OVERDOSAGE ..................................................................................................................9 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY..........................................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................11 PART II: SCIENTIFIC INFORMATION
    [Show full text]
  • Lithium Sulfate
    SIGMA-ALDRICH sigma-aldrich.com Material Safety Data Sheet Version 4.1 Revision Date 09/14/2012 Print Date 03/12/2014 1. PRODUCT AND COMPANY IDENTIFICATION Product name : Lithium sulfate Product Number : 203653 Brand : Aldrich Supplier : Sigma-Aldrich 3050 Spruce Street SAINT LOUIS MO 63103 USA Telephone : +1 800-325-5832 Fax : +1 800-325-5052 Emergency Phone # (For : (314) 776-6555 both supplier and manufacturer) Preparation Information : Sigma-Aldrich Corporation Product Safety - Americas Region 1-800-521-8956 2. HAZARDS IDENTIFICATION Emergency Overview OSHA Hazards Target Organ Effect, Harmful by ingestion. Target Organs Central nervous system, Kidney, Cardiovascular system. GHS Classification Acute toxicity, Oral (Category 4) GHS Label elements, including precautionary statements Pictogram Signal word Warning Hazard statement(s) H302 Harmful if swallowed. Precautionary none statement(s) HMIS Classification Health hazard: 1 Chronic Health Hazard: * Flammability: 0 Physical hazards: 0 NFPA Rating Health hazard: 1 Fire: 0 Reactivity Hazard: 0 Potential Health Effects Inhalation May be harmful if inhaled. May cause respiratory tract irritation. Aldrich - 203653 Page 1 of 7 Skin Harmful if absorbed through skin. May cause skin irritation. Eyes May cause eye irritation. Ingestion Harmful if swallowed. 3. COMPOSITION/INFORMATION ON INGREDIENTS Formula : Li2O4S Molecular Weight : 109.94 g/mol Component Concentration Lithium sulphate CAS-No. 10377-48-7 - EC-No. 233-820-4 4. FIRST AID MEASURES General advice Move out of dangerous area.Consult a physician. Show this safety data sheet to the doctor in attendance. If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
    [Show full text]
  • Oxytocin Regulates the Expression of Aquaporin 5 in the Latepregnant Rat
    RESEARCH ARTICLE Molecular Reproduction & Development 81:524–530 (2014) Oxytocin Regulates the Expression of Aquaporin 5 in the Late-Pregnant Rat Uterus ESZTER DUCZA,* ADRIENN B. SERES, JUDIT HAJAGOS-TOTH, GEORGE FALKAY, AND ROBERT GASPAR Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary SUMMARY Aquaporins (AQPs) are integral membrane channels responsible for the transport of water across a cell membrane. Based on reports that AQPs are present and accumulate in the female reproductive tract late in pregnancy, our aim was to study the expression of AQP isoforms (AQP1, 2, 3, 5, 8, and 9) at the end of pregnancy in rat in order to determine if they play a role in parturition. Reverse-transcriptase PCR revealed that specific Aqp mRNAs were detectable in the myometrium of non- pregnant and late-pregnancy (Days 18, 20, 21, and 22 of pregnancy) rat uteri. The expression of Aqp5 mRNA and protein were most pronounced on Days 18À21, and were dramatically decreased on Day 22 of pregnancy. In contrast, a significant increase was found in the level of Aqp5 transcript in whole-blood samples ÃCorresponding author: on the last day of pregnancy.The effect of oxytocin on myometrial Aqp5 expression in Department of Pharmacodynamics an organ bath was also investigated. The level of Aqp5 mRNA significantly decreased and Biopharmacy À8 University of Szeged, H-6720 5 min after oxytocin (10 M) administration, similarly to its profile on the day of Eotv€ os€ u. 6, Szeged 6270 delivery; this effect was sensitive to the oxytocin antagonist atosiban. The vasopres- Hungary.
    [Show full text]
  • Management and Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
    REVIEW Management and treatment of lithium- induced nephrogenic diabetes insipidus Christopher K Finch†, Lithium carbonate is a well documented cause of nephrogenic diabetes insipidus, with as Tyson WA Brooks, many as 10 to 15% of patients taking lithium developing this condition. Clinicians have Peggy Yam & Kristi W Kelley been well aware of lithium toxicity for many years; however, the treatment of this drug- induced condition has generally been remedied by discontinuation of the medication or a †Author for correspondence Methodist University reduction in dose. For those patients unresponsive to traditional treatment measures, Hospital, Department several pharmacotherapeutic regimens have been documented as being effective for the of Pharmacy, University of management of lithium-induced diabetes insipidus including hydrochlorothiazide, Tennessee, College of Pharmacy, 1265 Union Ave., amiloride, indomethacin, desmopressin and correction of serum lithium levels. Memphis, TN 38104, USA Tel.: +1 901 516 2954 Fax: +1 901 516 8178 [email protected] Lithium carbonate is well known for its wide use associated with a mutation(s) of vasopressin in bipolar disorders due to its mood stabilizing receptors. Acquired causes are tubulointerstitial properties. It is also employed in aggression dis- disease (e.g., sickle cell disease, amyloidosis, orders, post-traumatic stress disorders, conduct obstructive uropathy), electrolyte disorders (e.g., disorders and even as adjunctive therapy in hypokalemia and hypercalcemia), pregnancy, or depression. Lithium has many well documented conditions induced by a drug (e.g., lithium, adverse effects as well as a relatively narrow ther- demeclocycline, amphotericin B and apeutic range of 0.4 to 0.8 mmol/l. Clinically vincristine) [3,4]. Lithium is the most common significant adverse effects include polyuria, mus- cause of drug-induced nephrogenic DI [5].
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • Oral Desmopressin in Central Diabetes Insipidus
    Arch Dis Child: first published as 10.1136/adc.61.3.247 on 1 March 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 247-250 Oral desmopressin in central diabetes insipidus U WESTGREN, C WITTSTROM, AND A S HARRIS Department of Pediatrics, University Hospital, Lund, and Faculty of Pharmacy, Biomedicum, Uppsala, Sweden SUMMARY Seven paediatric patients with central diabetes insipidus were studied in an open dose ranging study in hospital followed by a six month study on an outpatient basis to assess the efficacy and safety of peroral administration of DDAVP (desmopressin) tablets. In the dose ranging study a dose dependent antidiuretic response was observed. The response to 12-5-50 mcg was, however, less effective in correcting baseline polyuria than were doses of 100 mcg and above. Patients were discharged from hospital on a preliminary dosage regimen ranging from 100 to 400 mcg three times daily. After an initial adjustment in dosage in three patients at one week follow up, all patients were stabilised on treatment with tablets and reported an adequate water turnover at six months. As with the intranasal route of administration dosage requirements varied from patient to patient, and a dose range rather than standard doses were required. A significant correlation, however, was found for the relation between previous intranasal and present oral daily dosage. No adver-se reactions were reported. No clinically significant changes were noted in blood chemistry and urinalysis. All patients expressed a preference for the oral over existing intranasal copyright. treatment. Treatment with tablets offers a beneficial alternative to the intranasal route, particularly in patients with chronic rhinitis or impaired vision.
    [Show full text]
  • Subchronic Lithium Treatment Increases the Anxiolytic-Like Effect of Mirtazapine on the Expression of Contextual Title Conditioned Fear
    Subchronic lithium treatment increases the anxiolytic-like effect of mirtazapine on the expression of contextual Title conditioned fear Author(s) An, Yan; Inoue, Takeshi; Kitaichi, Yuji; Nakagawa, Shin; Wang, Ce; Chen, Chong; Song, Ning; Kusumi, Ichiro European journal of pharmacology, 747, 13-17 Citation https://doi.org/10.1016/j.ejphar.2014.11.009 Issue Date 2015-01-15 Doc URL http://hdl.handle.net/2115/58243 Type article (author version) File Information AnManuscript.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Subchronic lithium treatment increases the anxiolytic-like effect of mirtazapine on the expression of contextual conditioned fear Yan Ana, Takeshi Inouea*, Yuji Kitaichia, Shin Nakagawaa, Ce Wangb, Chong Chena, Ning Songa, Ichiro Kusumia a Department of Psychiatry, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan b Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan Number of figures: 3 Corresponding address: Takeshi Inoue, Department of Psychiatry, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan Phone: +81(11)706-5160 Fax: +81(11)706-5081 E-mail: [email protected] 1 Abstract Lithium not only has a mood-stabilizing effect but also the augmentation effect of an antidepressant, the mechanism of which remains unclear. Although lithium may augment the effect of mirtazapine, this augmentation has not been confirmed. Using a contextual fear conditioning test in rats, an animal model of anxiety or fear, we examined the effect of subchronic lithium carbonate (in diet) in combination with systemic mirtazapine on the expression of contextual conditioned fear.
    [Show full text]
  • Relief of Nocturnal Enuresis by Desmopressin Is Kidney and Vasopressin Type 2 Receptor Independent
    JASN Express. Published on March 27, 2007 as doi: 10.1681/ASN.2006080907 Relief of Nocturnal Enuresis by Desmopressin Is Kidney and Vasopressin Type 2 Receptor Independent Joris H. Robben,* Mozes Sze,* Nine V. Knoers,† Paul Eggert,‡ Peter Deen,* and Dominik Mu¨ller§ *Department of Physiology, Nijmegen Centre of Molecular Life Sciences, and †Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; and ‡University Children’s Hospital, Kiel, and §Department of Pediatric Nephrology, Charite´Berlin, Berlin, Germany Primary nocturnal enuresis (PNE) is a common problem in childhood and adolescence. Although various treatments are highly effective, a common underlying hypothesis on the pathogenesis is lacking. The success of desmopressin, a synthetic analogue of the antidiuretic hormone vasopressin, has been attributed to increased renal water reabsorption that is mediated by activation of the renal vasopressin V2 receptor (V2R). However, this effect does not explain other symptoms of PNE, such as the failure to arouse upon bladder distension. This study identified a family in which one child displayed PNE and coexisting nephrogenic diabetes insipidus, as a result of a novel nonsense mutation in the V2R gene (C358X). Cell-biologic investigations revealed that V2R-C358X is retained in the endoplasmic reticulum and is unstable, which explains his nephrogenic diabetes insipidus. Consistently, extrarenal V2R-mediated responses were absent in the patient who was treated with desmopressin. Administration of desmopressin, however, changed his PNE into nocturia, because he now still voided unchanged high urinary volumes at night but woke up and went to the bathroom. Withdrawal of desmopressin was accompanied by bedwetting, whereas reintroduction again relieved the symptoms.
    [Show full text]
  • Hemmo Pharmaceuticals Private Limited
    Global Supplier of Quality Peptide Products Hemmo Pharmaceuticals Private Limited Corporate Presentation Privileged & Confidential Privileged & Confidential Corporate Overview Privileged & Confidential 2 Company at a glance • Commenced operations in 1966 as a Key Highlights trading house, focusing on Oxytocin amongst other products Amongst the largest Indian peptide manufacturing company • In 1979, ventured into manufacturing of Oxytocin Competent team of 154 people including 6 PhDs, 60+ chemistry graduates/post graduates and 3 engineers • Privately held family owned company Portfolio – Generic APIs, Custom Peptides for Research and Clinical Development and Peptide • Infrastructure Fragments − State of art manufacturing facility in Developed 21 generic products in-house. Navi Mumbai, 5 more in progress − R&D facilities at Thane and Spain − Corporate office at Worli First and the only independent Indian company to have a US FDA approved peptide manufacturing site Privileged & Confidential 3 Transition from a trading house to a research based manufacturing facility Commenced Commenced Investment in State of the Art Opened R& D Expanded operations manufacturing greenfield project facility at Navi Centre in manufacturing as a trading of peptides intended for Mumbai Girona,Spain capacity House regulated markets commissioned R&D center set up in Infrastructure Mumbai 1966 1979 2005 2007 2008 2010 2011 2012 2014 2015 Oxytocin Oxytocin Desmopressin Buserelin Triptorelin Goserelin Linaclotide Glatiramer amongst Gonadorelin Decapeptide Cetrorelix
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Lithium Sulfate, Technical Grade, Min. 99.0 %
    TECHNICAL DATA SHEET Date of Issue: 2018/02/15 Lithium Sulfate, technical grade, min. 99.0 % CAS-No. 10377-48-7 EC-No. 233-820-4 REACH No. 01-2119968668-14 Molecular Formula Li2O4S Product Number 401142 APPLICATION Additive for manufacturing special glass mixtures. Used for marking of chemical products. Additive in the building material industry. SPECIFICATION Li2SO4 min 99.0 % H2O (105 °C) max. 0.4 % Na max. 0.1 % K max. 0.05 % Fe max. 0.002 % Mg max. 0.01 % Heavy metals (as Pb) max. 0.004 % PHYSICAL PROPERTIES Appearance crystalline Color colorless to white Melting point/ range 860 °C Density 2.2 g/cm3 at 20 °C Bulk density ca. 800 kg/m3 Water solubility 342 g/L at 25 °C The information presented herein is believed to be accurate and reliable, but is presented without guarantee or responsibility on the part of Albemarle Corporation and its subsidiaries and affiliates. It is the responsibility of the user to comply with all applicable laws and regulations and to provide for a safe workplace. The user should consider any health or safety hazards or information contained herein only as a guide, and should take those precautions which are necessary or prudent to instruct employees and to develop work practice procedures in order to promote a safe work environment. Further, nothing contained herein shall be taken as an inducement or recommendation to manufacture or use any of the herein materials or processes in violation of existing or future patent. Technical data sheets may change frequently. You can download the latest version from our website www.albemarle-lithium.com.
    [Show full text]